A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
| dc.contributor.author | Serin, I | |
| dc.contributor.author | Dogu, MH | |
| dc.contributor.author | Ekinci, O | |
| dc.contributor.author | Cagliyan, GA | |
| dc.contributor.author | Bastürk, A | |
| dc.contributor.author | Aras, MR | |
| dc.contributor.author | Demircioglu, S | |
| dc.contributor.author | Turgut, B | |
| dc.contributor.author | Merter, M | |
| dc.contributor.author | Hacioglu, SK | |
| dc.contributor.author | Bagci, M | |
| dc.contributor.author | Albayrak, M | |
| dc.contributor.author | Korkmaz, S | |
| dc.contributor.author | Erkurt, MA | |
| dc.contributor.author | Dal, MS | |
| dc.contributor.author | Dursun, FE | |
| dc.contributor.author | Tombak, A | |
| dc.contributor.author | Aydogdu, I | |
| dc.contributor.author | Ulas, T | |
| dc.contributor.author | Altuntas, F | |
| dc.date.accessioned | 2025-04-10T10:37:25Z | |
| dc.date.available | 2025-04-10T10:37:25Z | |
| dc.description.abstract | Introduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: >= 35%) by imaging and control of hematocrit levels (<= 45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman's rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman's rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher's exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups. | |
| dc.identifier.e-issn | 2148-094X | |
| dc.identifier.issn | 2619-9793 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/43022 | |
| dc.language.iso | English | |
| dc.title | A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera | |
| dc.type | Article |